How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Pediatric HGG
Progressing
Recurrent
Survey
Treatment
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
30
11
2022
accepted:
05
01
2023
pubmed:
1
2
2023
medline:
10
3
2023
entrez:
31
1
2023
Statut:
ppublish
Résumé
As there is no standard of care treatment for recurrent/progressing pediatric high-grade gliomas (pHGG), we aimed to gain an overview of different treatment strategies. In a web-based questionnaire, members of the SIOPE-BTG and the GPOH were surveyed on therapeutic options in four case scenarios (children/adolescents with recurrent/progressing HGG). 139 clinicians with experience in pediatric neuro-oncology from 22 European countries participated in the survey. Most respondents preferred further oncological treatment in three out of four cases and chose palliative care in one case with marked symptoms. Depending on the case, 8-92% would initiate a re-resection (preferably hemispheric pHGG), combined with molecular diagnostics. Throughout all case scenarios, 55-77% recommended (re-)irradiation, preferably local radiotherapy > 20 Gy. Most respondents would participate in clinical trials and use targeted therapy (79-99%), depending on molecular genetic findings (BRAF alterations: BRAF/MEK inhibitor, 64-88%; EGFR overexpression: anti-EGFR treatment, 46%; CDKN2A deletion: CDK inhibitor, 18%; SMARCB1 deletion: EZH2 inhibitor, 12%). 31-72% would administer chemotherapy (CCNU, 17%; PCV, 8%; temozolomide, 19%; oral etoposide/trofosfamide, 8%), and 20-69% proposed immunotherapy (checkpoint inhibitors, 30%; tumor vaccines, 16%). Depending on the individual case, respondents would also include bevacizumab (6-18%), HDAC inhibitors (4-15%), tumor-treating fields (1-26%), and intraventricular chemotherapy (4-24%). In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressing HGG.
Identifiants
pubmed: 36720762
doi: 10.1007/s11060-023-04241-6
pii: 10.1007/s11060-023-04241-6
pmc: PMC9992031
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Temozolomide
YF1K15M17Y
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-538Informations de copyright
© 2023. The Author(s).
Références
Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 134(3):541–549. https://doi.org/10.1007/s11060-017-2393-0
doi: 10.1007/s11060-017-2393-0
pubmed: 28357536
Sturm D, Pfister SM, Jones DTW (2017) Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol 35(21):2370–2377. https://doi.org/10.1200/JCO.2017.73.0242
doi: 10.1200/JCO.2017.73.0242
pubmed: 28640698
Jones C, Karajannis MA, Jones DTW, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, Nicolaides T, Packer RJ, Persson AI, Phillips JJ, Simonds EF, Stafford JM, Tang Y, Pfister SM, Weiss WA (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 19(2):153–161. https://doi.org/10.1093/neuonc/now101
doi: 10.1093/neuonc/now101
pubmed: 27282398
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Bennett J, Erker C, Lafay-Cousin L, Ramaswamy V, Hukin J, Vanan MI, Cheng S, Coltin H, Fonseca A, Johnston D, Lo A, Zelcer S, Alvi S, Bowes L, Brossard J, Charlebois J, Eisenstat D, Felton K, Fleming A, Jabado N, Larouche V, Legault G, Mpofu C, Perreault S, Silva M, Sinha R, Strother D, Tsang DS, Wilson B, Crooks B, Bartels U (2020) Canadian pediatric neuro-oncology standards of practice. Front Oncol 10:593192. https://doi.org/10.3389/fonc.2020.593192
doi: 10.3389/fonc.2020.593192
pubmed: 33415075
pmcid: 7783450
Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF (2016) Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study. Neuro Oncol 18(10):1442–1450. https://doi.org/10.1093/neuonc/now038
doi: 10.1093/neuonc/now038
pubmed: 27006176
pmcid: 5035517
Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 13(3):317–323. https://doi.org/10.1093/neuonc/noq191
doi: 10.1093/neuonc/noq191
pubmed: 21339192
pmcid: 3064602
Vanan MI, Eisenstat DD (2015) DIPG in children—what can we learn from the past? Front Oncol 5:237. https://doi.org/10.3389/fonc.2015.00237
doi: 10.3389/fonc.2015.00237
pubmed: 26557503
pmcid: 4617108
Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH, Warmuth-Metz M, Bison B, Kortmann RD, Kramm CM (2018) Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen: acute toxicity in pediatric high-grade glioma patients. Strahlenther Onkol 194(3):215–224. https://doi.org/10.1007/s00066-017-1218-6
doi: 10.1007/s00066-017-1218-6
pubmed: 29022050
Su JM, Murray JC, McNall-Knapp RY, Bowers DC, Shah S, Adesina AM, Paulino AC, Jo E, Mo Q, Baxter PA, Blaney SM (2020) A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer 67(6):e28283. https://doi.org/10.1002/pbc.28283
doi: 10.1002/pbc.28283
pubmed: 32285998
Dufour C, Grill J, Lellouch-Tubiana A, Puget S, Chastagner P, Frappaz D, Doz F, Pichon F, Plantaz D, Gentet JC, Raquin MA, Kalifa C (2006) High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 42(17):2939–2945. https://doi.org/10.1016/j.ejca.2006.06.021
doi: 10.1016/j.ejca.2006.06.021
pubmed: 16962317
Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 7(2):165–77. https://doi.org/10.1007/BF00165101
doi: 10.1007/BF00165101
pubmed: 2550594
Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, Rutkowski S, Warmuth-Metz M, Kramm C (2011) High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol 102(3):433–442. https://doi.org/10.1007/s11060-010-0334-2
doi: 10.1007/s11060-010-0334-2
pubmed: 20694800
Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M (2018) Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and european society for pediatric oncology dipg registries. J Clin Oncol 36(19):1963–1972. https://doi.org/10.1200/JCO.2017.75.9308
doi: 10.1200/JCO.2017.75.9308
pubmed: 29746225
pmcid: 6075859
Wang SS, Bandopadhayay P, Jenkins MR (2019) Towards immunotherapy for pediatric brain tumors. Trends Immunol 40(8):748–761. https://doi.org/10.1016/j.it.2019.05.009
doi: 10.1016/j.it.2019.05.009
pubmed: 31229353
MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O’Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R (2005) Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children’s Cancer Group Study 9933. Cancer 104(12):2862–2871. https://doi.org/10.1002/cncr.21593
doi: 10.1002/cncr.21593
pubmed: 16315242
Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C):2437–2442 (PMID: 18751431)
pubmed: 18751431
Kline C, Felton E, Allen IE, Tahir P, Mueller S (2018) Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. J Neurooncol 137(1):103–110. https://doi.org/10.1007/s11060-017-2701-8
doi: 10.1007/s11060-017-2701-8
pubmed: 29204840
Tsang DS, Oliveira C, Bouffet E, Hawkins C, Ramaswamy V, Yee R, Tabori U, Bartels U, Huang A, Millar BA, Crooks B, Bowes L, Zelcer S, Laperriere N (2019) Repeat irradiation for children with supratentorial high-grade glioma. Pediatr Blood Cancer 66(9):e27881. https://doi.org/10.1002/pbc.27881
doi: 10.1002/pbc.27881
pubmed: 31207154
Müller K, Scheithauer H, Pietschmann S, Hoffmann M, Rössler J, Graf N, Baumert BG, Christiansen H, Kortmann RD, Kramm CM, von Bueren AO (2014) Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 9:177. https://doi.org/10.1186/1748-717X-9-177
doi: 10.1186/1748-717X-9-177
pubmed: 25112658
pmcid: 4283148
Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, Meyer B, Simon M, SN1 study group (2016) Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol 18(1):96–104. https://doi.org/10.1093/neuonc/nov145
doi: 10.1093/neuonc/nov145
pubmed: 26243790
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G, ITCC (Innovative Therapies for Children with Cancer) European Consortium (2011) Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 13(1):109–18. https://doi.org/10.1093/neuonc/noq141
doi: 10.1093/neuonc/noq141
pubmed: 20974795
Pfaff E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, Worst BC, Stark S, Witt H, Pajtler KW, van Tilburg CM, Witt R, Milde T, Jakobs M, Fiesel P, Frühwald MC, Hernáiz Driever P, Thomale UW, Schuhmann MU, Metzler M, Bochennek K, Simon T, Dürken M, Karremann M, Knirsch S, Ebinger M, von Bueren AO, Pietsch T, Herold-Mende C, Reuss DE, Kiening K, Lichter P, Eggert A, Kramm CM, Pfister SM, Jones DTW, Bächli H, Witt O (2019) Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. Eur J Cancer 114:27–35. https://doi.org/10.1016/j.ejca.2019.03.019
doi: 10.1016/j.ejca.2019.03.019
pubmed: 31022591
Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, Casanova M, Pecori E, Giangaspero F, Antonelli M, Buttarelli FR, Potepan P, Pollo B, Nunziata R, Spreafico F, Podda M, Anichini A, Clerici CA, Sardi I, De Cecco L, Bode U, Bach F, Gandola L (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol 118(2):305–312. https://doi.org/10.1007/s11060-014-1428-z
doi: 10.1007/s11060-014-1428-z
pubmed: 24696052
Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47. https://doi.org/10.1016/j.ejca.2016.12.007
doi: 10.1016/j.ejca.2016.12.007
pubmed: 28161497
Müller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Glück A, Pietschmann S, Wawer A, Kortmann RD, Kramm C, von Bueren AO (2014) Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group. Strahlenther Onkol. 190(4):377–81. https://doi.org/10.1007/s00066-013-0513-0
doi: 10.1007/s00066-013-0513-0
pubmed: 24638239
Weller M, Le Rhun E (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 87:102029. https://doi.org/10.1016/j.ctrv.2020.102029
doi: 10.1016/j.ctrv.2020.102029
pubmed: 32408220
Wagner S, Erdlenbruch B, Längler A, Gnekow A, Kühl J, Albani M, Völpel S, Bucsky P, Emser A, Peters O, Wolff JE (2004) Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the german society for pediatric oncology and hematology. Cancer 100(8):1750–1757. https://doi.org/10.1002/cncr.20168
doi: 10.1002/cncr.20168
pubmed: 15073866
Leonard A, Wolff JE (2013) Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer Res 33(8):3307–3315
pubmed: 23898097
Wolff JE, Mölenkamp G, Westphal S, Pietsch T, Gnekow A, Kortmann RD, Kuehl J (2000) Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 89(10):2131–2137. https://doi.org/10.1002/1097-0142(20001115)89:10%3c2131::aid-cncr14%3e3.0.co;2-j
doi: 10.1002/1097-0142(20001115)89:10<2131::aid-cncr14>3.0.co;2-j
pubmed: 11066055
Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol 15(1):4–27. https://doi.org/10.1093/neuonc/nos273
doi: 10.1093/neuonc/nos273
pubmed: 23136223
Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, Kramm CM (2010) Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer 116(3):705–712. https://doi.org/10.1002/cncr.24730
doi: 10.1002/cncr.24730
pubmed: 19957326
Vanan MI, Underhill DA, Eisenstat DD (2017) Targeting epigenetic pathways in the treatment of pediatric diffuse (high grade) gliomas. Neurotherapeutics 14(2):274–283. https://doi.org/10.1007/s13311-017-0514-2
doi: 10.1007/s13311-017-0514-2
pubmed: 28233220
pmcid: 5398987
Felix FH, de Araujo OL, da Trindade KM, Trompieri NM, Fontenele JB (2014) Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. J Neurooncol 116(2):261–266. https://doi.org/10.1007/s11060-013-1280-6
doi: 10.1007/s11060-013-1280-6
pubmed: 24293221
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, Balaguer Guill J, Baroni L, Bartels U, Bavle A, Bornhorst M, Boue DR, Canete A, Chintagumpala M, Coven SL, Cruz O, Dahiya S, Dirks P, Dunkel IJ, Eisenstat D, Faure Conter C, Finch E, Finlay JL, Frappaz D, Garre ML, Gauvain K, Bechensteen AG, Hansford JR, Harting I, Hauser P, Hazrati LN, Huang A, Injac SG, Iurilli V, Karajannis M, Kaur G, Kyncl M, Krskova L, Laperriere N, Larouche V, Lassaletta A, Leary S, Lin F, Mascelli S, McKeown T, Milde T, Morales La Madrid A, Morana G, Morse H, Mushtaq N, Osorio DS, Packer R, Pavelka Z, Quiroga-Cantero E, Rutka J, Sabel M, Salgado D, Solano P, Sterba J, Su J, Sumerauer D, Taylor MD, Toledano H, Tsang DS, Valente Fernandes M, van Landeghem F, van Tilburg CM, Wilson B, Witt O, Zamecnik J, Bouffet E, Hawkins C, Tabori U (2020) Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol. 4:561–571. https://doi.org/10.1200/PO.19.00298
doi: 10.1200/PO.19.00298
Toll SA, Tran HN, Cotter J, Judkins AR, Tamrazi B, Biegel JA, Dhall G, Robison NJ, Waters K, Patel P, Cooper R, Margol AS (2019) Sustained response of three pediatric BRAF
doi: 10.18632/oncotarget.26560
pubmed: 30728904
pmcid: 6355184
Gojo J, Pavelka Z, Zapletalova D, Schmook MT, Mayr L, Madlener S, Kyr M, Vejmelkova K, Smrcka M, Czech T, Dorfer C, Skotakova J, Azizi AA, Chocholous M, Reisinger D, Lastovicka D, Valik D, Haberler C, Peyrl A, Noskova H, Pál K, Jezova M, Veselska R, Kozakova S, Slaby O, Slavc I, Sterba J (2020) Personalized treatment of H3K27M-Mutant pediatric diffuse gliomas provides improved therapeutic opportunities. Front Oncol 9:1436. https://doi.org/10.3389/fonc.2019.01436
doi: 10.3389/fonc.2019.01436
pubmed: 31998633
pmcid: 6965319
Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, Castillo MR, Longchong M, Iznaga N, Lage A (2009) Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev 11(3):27–33. https://doi.org/10.37757/MR2009V11.N3.7
doi: 10.37757/MR2009V11.N3.7
pubmed: 21483304
Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, Rutkowski S, Beilken A, Schmid I, Biassoni V, Gorelishev SK, Kramm C, Reinhard H, Schlegel PG, Kortmann RD, Reuter D, Bach F, Iznaga-Escobar NE, Bode U (2019) Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neurooncol 143(1):107–113. https://doi.org/10.1007/s11060-019-03140-z
doi: 10.1007/s11060-019-03140-z
pubmed: 30830679
Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J (2010) Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 12(9):985–990. https://doi.org/10.1093/neuonc/noq033
doi: 10.1093/neuonc/noq033
pubmed: 20363768
pmcid: 2940690
Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G (2011) Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol 103(3):673–680. https://doi.org/10.1007/s11060-010-0444-x.1.Erratum.In:JNeurooncol.2011Jul;103(3):681
doi: 10.1007/s11060-010-0444-x.1.Erratum.In:JNeurooncol.2011Jul;103(3):681
pubmed: 21038110
Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G (2018) Phase II, Open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 36(10):951–958. https://doi.org/10.1200/JCO.2017.76.0611
doi: 10.1200/JCO.2017.76.0611
pubmed: 29412784
Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ (2017) The role of bevacizumab in the treatment of glioblastoma. J Neurooncol 133(3):455–467. https://doi.org/10.1007/s11060-017-2477-x
doi: 10.1007/s11060-017-2477-x
pubmed: 28527008
Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, Clymer J, Chi S, Yeo KK (2020) Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol 149(1):113–122. https://doi.org/10.1007/s11060-020-03578-6
doi: 10.1007/s11060-020-03578-6
pubmed: 32627129
Löhr M, Freitag B, Technau A, Krauss J, Monoranu CM, Rachor J, Lutz MB, Hagemann C, Kessler AF, Linsenmann T, Wölfl M, Ernestus RI, Engelhardt S, Gelbrich G, Schlegel PG, Eyrich M (2018) High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
doi: 10.1007/s00262-018-2214-0
pubmed: 30054667
pmcid: 6182405
Müller K, Henke G, Pietschmann S, van Gool S, De Vleeschouwer S, von Bueren AO, Compter I, Friedrich C, Matuschek C, Klautke G, Kortmann RD, Hundsberger T, Baumert BG (2015) Re-irradiation or re-operation followed by dendritic cell vaccination? comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model. J Neurooncol 124(2):325–332. https://doi.org/10.1007/s11060-015-1844-8
doi: 10.1007/s11060-015-1844-8
pubmed: 26070556
Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR (2021) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27(9):1544–1552. https://doi.org/10.1038/s41591-021-01404-8
doi: 10.1038/s41591-021-01404-8
pubmed: 34253928
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718.Erratum.In:JAMA.2018May1;319(17):1824
doi: 10.1001/jama.2017.18718.Erratum.In:JAMA.2018May1;319(17):1824
pubmed: 29260225
pmcid: 5820703
Green AL, Mulcahy Levy JM, Vibhakar R, Hemenway M, Madden J, Foreman N, Dorris K (2017) Tumor treating fields in pediatric high-grade glioma. Childs Nerv Syst 33(7):1043–1045. https://doi.org/10.1007/s00381-017-3431-0
doi: 10.1007/s00381-017-3431-0
pubmed: 28470383
Crawford J, Saria MG, Dhall G, Margol A, Kesari S (2020) Feasibility of treating high grade gliomas in children with tumor-treating fields: a case series. Cureus 12(10):e10804. https://doi.org/10.7759/cureus.10804
doi: 10.7759/cureus.10804
pubmed: 33163308
pmcid: 7641478